VBI-2902
N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Other names | VBI-2902a |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
.svg.png.webp){kind=small} COVID-19 portal |
History
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[2] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[2] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[2][3][4] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[5]
References
- Philippidis, Alex (1 November 2021). "Six Up-and-Coming COVID-19 Vaccines". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 December 2021.
- "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. 9 March 2021. Retrieved 22 March 2021.
- "VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 March 2022.
- VBI Vaccines Inc. (1 October 2021). "A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults".
{{cite journal}}: Cite journal requires|journal=(help) - Curran M, Sali D, Kovessy P (August 2020). "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. Retrieved 22 March 2021.
External links
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.